ALLR (STOCKS)
Allarity Therapeutics, Inc. Common Stock
$1.480000
+0.050000 (+3.50%)
Prev close: $1.430000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Thomas H. Jensen
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $23.23M
- Employees
- 7
- P/E (TTM)
- -2.05
- P/B (TTM)
- 3.27
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
2
Strong Buy
4
Buy
1
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Mar 2026 (Q1)
|
$-0.17 | $-0.22 | +0.0544 | +24.24% |
|
Sep 2025 (Q3)
|
$-0.19 | $-0.23 | +0.0446 | +19.01% |
|
Jun 2025 (Q2)
|
$-0.15 | $-0.21 | +0.0642 | +29.97% |
|
Sep 2024 (Q3)
|
$-7.71 | $-8.69 | +0.9804 | +11.28% |
Financial Statements
| Revenues | $345.00K |
| Nonoperating Income/Loss | $1.01M |
| Operating Expenses | $12.60M |
| Research and Development | $6.50M |
| Other Operating Expenses | $6.11M |
| Operating Income/Loss | -$12.26M |
| Income/Loss From Continuing Operations After Tax | -$11.25M |
| Income/Loss From Continuing Operations Before Tax | -$8.47M |
| Net Income/Loss | -$11.25M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$11.25M |
| Net Income/Loss Available To Common Stockholders, Basic | -$11.25M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$0.72 |
| Basic Average Shares | 46,780,678 |
| Assets | $34.92M |
| Current Assets | $34.50M |
| Prepaid Expenses | $3.50M |
| Other Current Assets | $31.00M |
| Noncurrent Assets | $420.00K |
| Fixed Assets | $420.00K |
| Liabilities | $28.00M |
| Current Liabilities | $28.00M |
| Accounts Payable | $4.24M |
| Other Current Liabilities | $23.77M |
| Noncurrent Liabilities | $0.00 |
| Equity | $6.92M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $6.92M |
| Liabilities And Equity | $34.92M |
| Net Cash Flow From Operating Activities | -$16.63M |
| Net Cash Flow From Operating Activities, Continuing | -$16.63M |
| Net Cash Flow From Investing Activities | $8.39M |
| Net Cash Flow From Investing Activities, Continuing | $8.39M |
| Net Cash Flow From Financing Activities | $19.25M |
| Net Cash Flow From Financing Activities, Continuing | $19.25M |
| Net Cash Flow | $11.00M |
| Net Cash Flow, Continuing | $11.00M |
| Comprehensive Income/Loss | -$9.87M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$11.70M |
| Other Comprehensive Income/Loss | -$7.55M |